Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents.
Winnie Y ZouKati ChoiJennifer R KramerXian YuYumei CaoHashem B El-SeragFasiha KanwalPublished in: Digestive diseases and sciences (2019)
We conclude that most HCV+ patients with HCC benefit from DAA treatment; however, timing of DAA initiation after HCC treatment should be carefully considered.